Concepedia

Greg de Hart

GD

Statistics

Publications

4

Citations

84

H-Index

4

Active since

2018

Affiliations

BioMarin (United States)(Current)

Greg de Hart is an author at BioMarin (United States) specializing in life sciences, immunology, and immunotherapy.

Publications per year

2018–2024

4

Publications

4

Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study

Anu Cherukuri, Heather Cahan, Greg de Hart et al. · Clinical Immunology · 2018 · 36 citations

Life Sciences, Immunology, Pharmacotherapy +3

Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A

Brian R Long, Tara M. Robinson, Jonathan R S Day et al. · Molecular Therapy · 2024 · 25 citations · Full text

Life Sciences, Hematology, Immunology +13

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration

Aryun Kim, Anita Grover, Kevin Hammon et al. · Clinical and Translational Science · 2020 · 13 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease

Kevin Hammon, Greg de Hart, Brian R. Vuillemenot et al. · Clinical and Translational Science · 2021 · 10 citations · Full text

Medicine, Neuroscience, Pharmacology +17

1–4 of 4